MediaAlpha (MAX) Q2 2024 earnings summary

Executive summary

• Q2 2024 saw record performance with revenue of $178.3 million, up 110% year-over-year, and Transaction Value of $321.8 million, up 156% year-over-year, driven by a strong recovery in the Property & Casualty (P&C) insurance vertical.

• Net income reached $4.4 million, reversing a net loss of $20.0 million in Q2 2023, with Adjusted EBITDA up 422% to $18.7 million.

• P&C insurance led growth, with Transaction Value up over 300% year-over-year, now representing 75–79% of total Transaction Value.

• Health insurance vertical delivered solid growth, with Transaction Value up 9% year-over-year and expected to contribute about 20% of 2024 Transaction Value, though revenue declined due to a partner exit.

• Management remains optimistic about continued favorable market conditions into 2025 but notes uncertainty beyond Q3 2024.

Financial highlights

• Gross profit for Q2 2024 was $31.7 million, with gross margin improving to 17.8% from 16.2% a year ago.

• Adjusted EBITDA margin expanded to 10.5% due to operating leverage.

• Cash and cash equivalents increased to $28.7–$29 million, with $14 million generated in Q2 and $23.3 million in operating cash flow for the first half of 2024.

• Diluted EPS was $0.07, compared to $(0.32) in Q2 2023.

• Q2 included $700,000 in legal expenses (FTC inquiry), $600,000 in legal/accounting (secondary offerings), and a $1.7 million one-time contract termination fee from a health partner exit.

Outlook and guidance

• Q3 2024 revenue expected between $240 million and $255 million, up over 230% year-over-year at midpoint.

• Q3 Transaction Value projected at $415–$435 million, up 290% year-over-year at midpoint.

• Q3 Adjusted EBITDA guidance: $22–$24 million, up over 540% year-over-year at midpoint.

• Overhead expected flat to slightly up in Q3, with a $1 million increase in Q4 for selective headcount growth; legal costs for FTC inquiry expected to remain similar in Q3.

• Management expects continued improvement in the P&C market but cannot predict the pace or impact of recovery beyond Q3 2024.